Study guide
5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures
ARRT Radiation Therapy Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient Care & Education
1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation
2 Chapter 2: Radiation Physics, Radiobiology & Protection
2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients
3 Chapter 5: Treatment Sites, Tumors & Classification
5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems
4 Chapter 3: Treatment Planning & Dosimetry
3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances
5 Chapter 4: Treatment Delivery, Image Guidance & QA
4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation
5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures
Key Takeaways Explain This Topic AI
Mediastinal and hilar lymph nodes are mapped using standardized IASLC stations; the subcarinal station (7) can receive drainage from either lung.
NSCLC spreads locally by direct extension and orderly lymphatic progression, while SCLC spreads early and hematogenously with a high rate of brain metastases.
Spinal cord, esophagus, heart, lungs (V20/mean lung dose), and brachial plexus (for apical tumors) are the principal dose-limiting structures in thoracic radiotherapy.
Lung cancer classically disseminates hematogenously to the brain, bone, liver, and adrenal glands.
4D-CT simulation and motion management (ITV, breath-hold, gating) account for respiratory tumor motion, which is especially critical for SBRT.
Last updated: July 2026
Anatomy and Nodal Stations
The right lung has three lobes (upper, middle, lower) separated by the horizontal and oblique fissures; the left lung has two lobes (upper, lower) separated by the oblique fissure, with the lingula as an analog to the right middle lobe. Each lung is invested by visceral pleura, with a thin pleural space separating it from the parietal pleura lining the chest wall; the mediastinum contains the heart, great vessels, trachea, esophagus, and thymus, and separates the two pleural cavities. The hilum, where the mainstem bronchus, pulmonary artery, and pulmonary veins enter and exit each lung, is a common site of central tumor involvement and lymphatic convergence.
Mediastinal and hilar lymph nodes are mapped using the standardized IASLC lymph node map, grouped into stations that are essential for staging (the N-descriptor) and for designing elective or involved-field nodal irradiation:
- Nodal Station Group Example Stations Typical Drainage
- Supraclavicular Station 1 Apical tumors, advanced disease
- Superior mediastinal Stations 2, 3, 4 Upper lobe tumors, especially right-sided
- Aortic/subaortic Stations 5, 6 Left upper lobe tumors
- Inferior mediastinal/subcarinal Stations 7, 8, 9 Lower lobe tumors, central tumors of either lung
- Hilar/interlobar Stations 10, 11 Peripheral and central tumors of the ipsilateral lung
The subcarinal station (station 7) is a particularly important convergence point because it can receive drainage from either lung and from multiple lobes, making it a common site of nodal involvement regardless of the laterality of the primary tumor.
Patterns of Spread
Locally, non-small cell lung cancer (NSCLC) spreads by direct extension into adjacent structures -- chest wall, mediastinum, great vessels, esophagus, or vertebral bodies -- and by lymphatic spread following an orderly progression from intrapulmonary/hilar nodes to mediastinal stations, generally respecting lobar and laterality patterns (though the subcarinal station is a notable exception). Malignant pleural effusion indicates pleural surface involvement and, along with pleural or pericardial nodules, typically upstages disease to a status generally not amenable to curative-intent radiotherapy alone.
Small cell lung cancer (SCLC) is far more aggressive, with a strong tendency toward early hematogenous dissemination; it frequently presents with bulky mediastinal adenopathy and has a high rate of subclinical or overt brain metastases, which is why prophylactic cranial irradiation (PCI) or close MRI surveillance has historically been considered for patients responding well to initial chemoradiation.
Distant metastatic spread for lung cancer in general most commonly targets the brain, bone, liver, and adrenal glands, reflecting the pattern expected from hematogenous seeding through the pulmonary venous circulation. Adrenal metastases are common enough that isolated adrenal nodules found on staging imaging require careful workup before assuming a benign etiology (such as a benign adenoma) in a lung cancer patient.
Critical Structures, Motion Management, and Therapist Considerations
Thoracic radiotherapy planning must account for both dose-limiting normal structures and the fact that the thorax is in constant motion from respiration:
Spinal cord: a hard maximum point-dose constraint avoids myelopathy, particularly relevant since the cord runs immediately posterior to central mediastinal targets.
Esophagus: acute esophagitis (odynophagia, dysphagia) is common during concurrent chemoradiation for centrally located or mediastinal disease and can affect nutrition and treatment tolerance.
Heart: mean heart dose and dose to specific cardiac substructures correlate with cardiac events and, in some studies, overall survival, making cardiac sparing an increasing planning priority.
Lungs: mean lung dose and the volume of lung receiving 20 Gy (V20) are the principal predictors of symptomatic radiation pneumonitis; these constraints often limit how much dose can be delivered, especially with larger target volumes.
Brachial plexus: critical for apical (superior sulcus/Pancoast) tumors, where the plexus may be immediately adjacent to or invaded by tumor.
Because tumors and nodal targets move with breathing, four-dimensional CT (4D-CT) simulation captures the tumor position throughout the full respiratory cycle, allowing an internal target volume (ITV) to be constructed that encompasses the entire range of tumor motion rather than relying on a single-phase snapshot. Motion management strategies include free-breathing with ITV-based margins, breath-hold techniques, and respiratory gating, where the beam is only active during a defined portion of the breathing cycle. For early-stage, medically inoperable NSCLC, stereotactic body radiotherapy (SBRT) delivers a small number of very high-dose, highly conformal fractions and depends heavily on accurate motion management and image guidance (daily CBCT) because the ablative per-fraction doses leave very little margin for geographic miss. Immobilization typically uses a wing board or vacuum-bag body cradle with arms positioned overhead to keep them out of the beam path, and daily or frequent image guidance verifies both tumor position and any interval changes such as atelectasis, effusion, or tumor regression that could necessitate a replan.
Staging with PET/CT and, when feasible, endobronchial ultrasound or mediastinoscopy for suspicious nodal stations is essential before curative-intent treatment planning, since accurate nodal staging directly determines whether elective nodal coverage, involved-field-only treatment, or a switch to systemic/palliative management is appropriate. Concurrent chemoradiation remains standard for locally advanced, unresectable NSCLC, while SBRT is generally reserved for small, node-negative, peripheral tumors where ablative focal dose can be delivered safely without excessive normal-tissue exposure. Because central tumors sit close to the proximal bronchial tree, esophagus, and great vessels, SBRT to central lesions requires more conservative fractionation than peripheral SBRT to avoid serious airway or vascular injury.